facebook tracking

Department of Pharmaceuticals

DoP Corrigendum on Modifications to Appendix B of the PLI Scheme for Pharmaceuticals – Group C (MSME)


regulatory illustration
Importer & Manufacturer   |   Source: Department of Pharmaceuticals
Published On: 30-10-2026

Enforcement Date: 30 November, 2026
DoP Corrigendum on Modifications to Appendix B of the PLI Scheme for Pharmaceuticals – Group C (MSME)

The Department of Pharmaceuticals issued a corrigendum revising the minimum cumulative investment schedule for Group C (MSME) participants under the Production Linked Incentive (PLI) Scheme for Pharmaceuticals. The amendment provides beneficiaries with an additional year to meet the prescribed investment milestones while retaining the existing sales-growth eligibility criteria and other scheme provisions.


The Department of Pharmaceuticals has amended Appendix B of the operational guidelines for Group C (MSME) applicants under the PLI Scheme for Pharmaceuticals. The corrigendum revises the minimum cumulative investment schedule, extending the timeline for beneficiaries to achieve the required investment milestones.


Key points include:

  1. The minimum cumulative investment requirement is 20% by FY 2022 to 23, 40% by FY 2023 to 24, 60% by FY 2024 to 25, 80% by FY 2025 to 26 and 100% by FY 2026 to 27.
  2. Eligible applicants must submit fresh incentive claims for previous performance years, which will be examined under the applicable scheme guidelines and procedures.
  3. Existing year-on-year sales-growth eligibility criteria remain unchanged.
  4. Performance years for calculating incremental sales and incentive disbursement remain FY 2022 to 23 to FY 2027 to 28.
  5. All other provisions of the operational guidelines and subsequent amendments remain unchanged.

Applicable For: Importer & Manufacturer
Reference Number: 3५०. 3026/60/2020-720॥09 Notification Link

Related Regulatory Updates

Contact us

Please feel free to talk to us if you have any questions. We endeavour to answer within 24 hours.